Stephens Inc. AR Has $273,000 Stake in Castle Biosciences, Inc. (NASDAQ:CSTL)

Stephens Inc. AR trimmed its stake in Castle Biosciences, Inc. (NASDAQ:CSTL) by 5.5% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 13,639 shares of the company’s stock after selling 800 shares during the period. Stephens Inc. AR’s holdings in Castle Biosciences were worth $273,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in Castle Biosciences by 4.3% in the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 14,786 shares of the company’s stock valued at $394,000 after buying an additional 608 shares in the last quarter. Invesco Ltd. boosted its position in Castle Biosciences by 2.3% in the fourth quarter. Invesco Ltd. now owns 27,534 shares of the company’s stock valued at $734,000 after buying an additional 616 shares in the last quarter. Diversify Wealth Management LLC boosted its position in Castle Biosciences by 5.8% in the first quarter. Diversify Wealth Management LLC now owns 13,102 shares of the company’s stock valued at $260,000 after buying an additional 717 shares in the last quarter. Teacher Retirement System of Texas boosted its position in Castle Biosciences by 9.6% in the first quarter. Teacher Retirement System of Texas now owns 10,383 shares of the company’s stock valued at $208,000 after buying an additional 908 shares in the last quarter. Finally, Covestor Ltd acquired a new position in Castle Biosciences in the fourth quarter valued at about $25,000. 92.60% of the stock is currently owned by institutional investors and hedge funds.

Castle Biosciences Stock Down 4.9%

Shares of NASDAQ:CSTL opened at $16.54 on Monday. The company has a market capitalization of $477.51 million, a PE ratio of -87.05 and a beta of 1.10. Castle Biosciences, Inc. has a 52 week low of $15.45 and a 52 week high of $35.84. The company has a debt-to-equity ratio of 0.02, a quick ratio of 9.19 and a current ratio of 9.37. The company has a 50 day moving average price of $18.09 and a two-hundred day moving average price of $21.37.

Castle Biosciences (NASDAQ:CSTL) last announced its earnings results on Monday, May 5th. The company reported ($0.20) EPS for the quarter, missing the consensus estimate of ($0.08) by ($0.12). Castle Biosciences had a positive return on equity of 3.41% and a negative net margin of 1.46%. The business had revenue of $87.99 million for the quarter, compared to analyst estimates of $80.40 million. Analysts forecast that Castle Biosciences, Inc. will post 0.44 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of equities analysts have commented on the stock. Lake Street Capital reduced their price target on shares of Castle Biosciences from $40.00 to $35.00 and set a “buy” rating on the stock in a research report on Tuesday, May 6th. Scotiabank reduced their target price on shares of Castle Biosciences from $44.00 to $40.00 and set a “sector outperform” rating on the stock in a research report on Wednesday, May 21st. Guggenheim set a $30.00 target price on shares of Castle Biosciences and gave the stock a “buy” rating in a research report on Friday, March 28th. Finally, Canaccord Genuity Group reduced their target price on shares of Castle Biosciences from $42.00 to $37.00 and set a “buy” rating on the stock in a research report on Tuesday, May 6th. Eight equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company presently has an average rating of “Buy” and an average price target of $37.00.

About Castle Biosciences

Castle Biosciences, Inc, a molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus, uveal melanoma, and mental health conditions. It offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma; DecisionDx-SCC, a proprietary risk stratification GEP test for patients with cutaneous squamous cell carcinoma; MyPath Melanoma, a test used for patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a spatial omics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, or low-grade dysplasia Barrett's esophagus.